Меню
Идёт набор NCT07691775

A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors

Фаза I / Фаза II С лечением Solid Tumor

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: F18 FBPA Injection.
Кому может быть актуально
Состояния в реестре: Solid Tumor. Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Тайвань
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

This Phase I/II clinical study, titled "A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors", aims to evaluate the safety and diagnostic performance of F18 FBPA PET/CT imaging in subjects with solid tumors. The primary objective is to evaluate the safety and establish the optimal screening conditions (including dose, timing and image quality) of F18 FBPA PET/CT in patients with solid tumors.

Вмешательства

  • Препарат F18 FBPA Injection
    F18 FBPA (4-Borono-2-\[18F\]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used in positron emission tomography (PET) for tumor imaging. Its uptake is mainly facilitated by the L-type amino acid transporter 1 (LAT1), which is commonly overexpressed in malignant tumors. This selective transport mechanism allows F18 FBPA to accumulate preferentially in tumor tissues rather than in normal tissues. Once taken up by cells, the fluorine-18 isotope emits positrons, enabling accurate vis

Первичные конечные точки

  • To evaluate the safety and establish the optimal screening conditions (including dose, timing and image quality) of F18 FBPA PET/CT in patients with solid tumors [Срок оценки: 6 months]
Вторичные конечные точки (1)
  • To evaluate the applicability of F18 FBPA PET/CT imaging for tumor detection across various solid tumor types. [Срок оценки: 6 months]

Критерии участия

Критерии включения

  • Subject aged 18-80 (inclusive).
  • Histopathological confirmed diagnosis of a solid tumor (including but not limited to osteogenic sarcoma, brain tumors, head and neck cancer, lung cancer, breast cancer, or colorectal cancer).
  • At least one measurable lesion identified on prior imaging evaluation, assessed by RECIST version 1.1.
  • Willingness to undergo PET/CT scan.
  • Provision of signed informed consent.

Критерии исключения

  • Body weight > 80 kg at screening.
  • Any contraindication to PET, including active breastfeeding. Female subjects of reproductive potential must have a negative serum pregnancy test at screening.
  • History of claustrophobic reactions.
  • History of phenylketonuria.
  • History of research-related radiation exposure exceeding the Nuclear Safety Commission's current guideline of 50 mSv within the past 12 months.
  • Inability to lie comfortably in a supine position for more than 60 minutes.as assessed by physical examination and medical history (e.g., back pain, severe arthritis).
  • Subjects from other at-risk populations, including minors, cognitively impaired individuals.
  • Suspected or known hypersensitivity (including allergy) to any F18 FBPA components or contrast media
  • Hereditary fructose intolerance.
  • A greater risk than normal for potential cardiac arrest such as history of non-compensated congestive heart failure, poorly controlled arrythmias or symptomatic non compensated cardiopathies.
  • Inadequate organ function within 30 days prior to the F18 FBPA PET/CT, defined as:

QTc > 460 msec; Serum Albumin < 2.8 mg/mL; Total Bilirubin > 3.0 mg/mL; ALT ≥ 400 U/L and/or AST ≥ 400 U/L; Creatinine < 0.5 mg/dL or > 1.4 mg/dL; eGFR < 60 mL/min/1.73 m2

  • Any medical or psychiatric conditions under the supervision of the investigator may interfere with optimal participation in the study or place the subject at increased risk of AEs.
  • History of radiation therapy within 3 months prior to the screening visit.
  • History of renal impairments, including nephrolithiasis, nephrotic syndrome, or hematuria, and/or other severe renal conditions in the opinion of the investigator.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Диагностика

Центры проведения

Тайвань · 1 центр
  • Taipei Veterans General Hsopital — Taipei

Идентификаторы

NCT: NCT07691775 · HN-FBPA-001

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗